This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Delea TE, Karnon J, Sofrygin O, Thomas SK, Barghout V.Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer. Breast Cancer Research and Treatment 100 (Suppl. 1): 116-117 (plus poster) abstr. 2107, Dec 2006
Lundkvist J, Paulsson T, Borgstrom F, Kasteng F, Sobocki P, Lidgren M, Henriksson R.Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial. Breast Cancer Research and Treatment 100 (Suppl. 1): 229 (plus poster) abstr. 5048, Dec 2006
Maurer SM, Seitz A, von Schwerin A, Ulm K, Kolben M.Cost-effectiveness of the adjuvant enodcrine therapy for patients with primary breast cancer in Germany: tamoxifen versus exemestane. Breast Cancer Research and Treatment 100 (Suppl. 1): 229-230 (plus poster) abstr. 5050, Dec 2006
Younis T, Rayson D, Sellon M, Skedgel C.Cost-utility of adjuvant chemotherapy in breast cancer: FEC-Doc [5-flurouracil (F), epirubicin (E), cyclophosphamide (C) - docetaxel] compared to FEC 100. Breast Cancer Research and Treatment 100 (Suppl. 1): 231 (plus poster) abstr. 5054, Dec 2006
Rights and permissions
About this article
Cite this article
News from SABCS. Pharmacoecon. Outcomes News 521, 5 (2007). https://doi.org/10.2165/00151234-200705210-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705210-00015